Literature DB >> 6562983

[Lipoprotein changes during hormonal treatment of endometriosis with lynestrenol and danazol].

A T Teichmann, H Wieland, P Cremer, W Kuhn, D Seidel.   

Abstract

The Lipoprotein profile of 24 patients with endometriosis was determined before, during and after the treatment with the two steroid hormones Lynestrenol (10 mg/day) and Danazol (600-800 mg/day). The total cholesterol triglycerides, beta-, prebeta-, and Alphalipo -protein bound to cholesterol were determined. Both hormones cause a marked lowering of the Alpha-Lp-cholesterin. In addition, the beta-LP-cholesterin was elevated and the beta-alpha-LP-ratio was elevated. In the dosage used by us, Lynestrenol showed less effect on the Lipoprotein profile. Danazol caused changed in the beta- and alpha-lipoprotein pattern of highly pathological atherogenic types. The total cholesterol was not influenced. Since women in the fertile age group will suffer a higher risk of arteriosclerosis from an elevation of the beta-LP-cholesterin, the treatment with Danazol calls for a sophisticated monitoring of the lipid metabolism and care in the indication for long term treatment with Danazol or with Lynestrenol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6562983     DOI: 10.1055/s-2008-1036873

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  1 in total

1.  LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation.

Authors:  U Cirkel; K W Schweppe; H Ochs; J P Hanker; H P Schneider
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.